Olympus launches first applications in OLYSENSE AI portfolio
Med-Tech Insights reports that Olympus has launched the first three applications in its OLYSENSE CAD/AI portfolio, initially in selected European countries. These AI-powered, cloud-based tools are designed to support clinicians in detecting and characterising tissues and lesions during endoscopy.
The portfolio includes CADDIE, which assists in identifying colorectal polyps in real time, CADU, which targets dysplasia in Barrett’s Esophagus, and SMARTIBD, which supports assessment of ulcerative colitis through MAYO scoring. All three are CE-approved under the Medical Device Regulations (MDR).
This launch reflects the growing role of AI-powered diagnostic support tools in MedTech, providing clinicians with enhanced decision-making capabilities and improving patient care pathways.
🔗 Read the full article on Med-Tech Insights: Olympus launches first applications in OLYSENSE AI portfolio
Credit for images and content: Med-Tech Insights
____________________________________________________________________________________________________________________________________________________________________________________________________
Cure Talent is a recruitment agency dedicated to the medical technology industry. Whether you are looking for a new role in the medical device sector or you’re an innovative medical device, digital health, or biotech company looking for staff, get in touch with the team today and explore how Cure Talent can help!